minimally invasive approaches in the treatment of urothelial carcinoma robotic radical cystectomy
Download
Skip this Video
Download Presentation
Douglas S. Scherr, M.D. Weill Medical College of Cornell University

Loading in 2 Seconds...

play fullscreen
1 / 40

Douglas S. Scherr, M.D. Weill Medical College of Cornell University - PowerPoint PPT Presentation


  • 114 Views
  • Uploaded on

Minimally Invasive Approaches in the Treatment of Urothelial Carcinoma “ Robotic Radical Cystectomy ”. Douglas S. Scherr, M.D. Weill Medical College of Cornell University. Robotics Beyond The Prostate. Radical Cystectomy Can we achieve equal oncological outcome?. Radical Cystectomy.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Douglas S. Scherr, M.D. Weill Medical College of Cornell University' - nickan


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
minimally invasive approaches in the treatment of urothelial carcinoma robotic radical cystectomy

Minimally Invasive Approaches in the Treatment of Urothelial Carcinoma“Robotic Radical Cystectomy”

Douglas S. Scherr, M.D.

Weill Medical College of Cornell University

robotics beyond the prostate
Robotics Beyond The Prostate
  • Radical Cystectomy
  • Can we achieve equal oncological outcome?
radical cystectomy
Radical Cystectomy
  • Gold Standard for Invasive Disease
  • Role in T1 Disease
  • Quality of surgery impacts outcome and survival
was the effect all chemotherapy are surgical variables important
Was the Effect all Chemotherapy?Are surgical variables important?
  • Post cystectomy survival predicted by: a.) age b.) stage c.) node status d.) negative surgical margins e.) >10 nodes removed
  • Hazard ratio for death: a.) 2.7 for + surgical margin b.) 2.0 for <10 nodes removed

Herr et al. JCO, 22(14): 2781, 2004

radical cystectomy for t1 tcc
Radical Cystectomy for T1 TCC
  • USC Experience: 208 pts with T1 disease
  • USC Experience with T2 disease

Recurrence Free Survival Overall Survival

5 Year 10 Year 5 Year 10 Year

80% 75% 74% 51%

Recurrence Free Survival Overall Survival

5 Year 10 Year 5 Year 10 Year

81% 80% 72% 56%

Stein et al., J Clin Oncol, 19(3): 666-75, 2001

early vs late cystectomy
Early Vs. Late Cystectomy
  • 90 pts who had TUR + BCG ultimately underwent cystectomy
  • 41/90 had T1 disease
  • Median Follow up of 96 mos Early cystectomy (<2 years): 92% survival Late cystectomy (>2 years): 56% survival

Herr and Sogani, J Urol, 166: 1296-9, 2001

extent of lymphadenectomy
Extent of Lymphadenectomy
  • Is there more to the node dissection than staging?
  • 1936 Colston and Leadbetter performed studies on 98 cadavers “limited metastatic disease was restricted to the pelvic nodes”
  • 1946 – Dr. Jewett “cardinal site of metastasis”

Colston and Leadbetter, J Urol, 36: 669, 1936

Jewett et al. J Urol, 55: 366, 1946

extent of lymphadenectomy1
Extent of Lymphadenectomy
  • Node positive patients can enjoy long term survival
  • 24% of grossly node positive disease survived 10 years without adjuvant therapy
  • More nodes removed correlates with improved survival

Sanderson et al. Urol Oncol., 22: 205, 2004

extent of lymphadenectomy2
Extent of Lymphadenectomy
  • Likely no staging advantage to extending the node dissection above the aortic bifurcation
  • 33% of unsuspected nodes found at common iliacs
  • Practice patterns vary widely:

a.) 40% of cystectomies have no LND b.) 12.7% of LND had <4 nodes removed

Lymph node density (# pos nodes/total # nodes)

Konety et al. J Urol, 170: 1765, 2003

slide12

Extent of Pelvic Lymph Node Dissection

IMA

Genitofemoral

nerve

Genitofemoral

nerve

Aortic

Nodes

Common Iliac Nodes

Hypogastric and

Obturator Nodes

slide13

Survival By Number Of Lymph Nodes Removed

Herr et al. JCO, 22(14): 2781, 2004

slide14

Postcystectomy survival by node status and number of nodes removed

Herr, H. W. et al. J Clin Oncol; 22:2781-2789 2004

post cystectomy survival
Post Cystectomy Survival

Herr, H. W. et al. J Clin Oncol; 22:2781-2789 2004

gold standard
Gold Standard
  • Open radical cystectomy (RC) is the gold standard for treatment of muscle-invasive bladder cancer.
minimally invasive bladder cancer surgery
Minimally Invasive Bladder Cancer Surgery
  • Efforts to reduce the operative morbidity of RC have fostered interest in minimally invasive approaches.
  • Laparoscopic RC
  • Robot-assisted laparoscopic RC
concerns of robotic cystectomy
Concerns of Robotic Cystectomy?
  • Concerns regarding minimally invasive RC
    • Absence of long term oncologic outcomes
    • Absence of long term functional outcomes
    • Limited pelvic lymphadenectomy
    • Longer operative time
    • Increased cost

Miller NL et al: World J Urol (2006) 24:180

outcome measures of minimally invasive bladder surgery
Outcome Measures of Minimally Invasive Bladder Surgery
  • Previous reports comparing open versus minimally invasive RC have focused on perioperative outcomes.
    • Blood loss
    • Operative time
    • Analgesic requirement
    • Time to regular diet
    • Length of hospital stay

Hemal AK et al: Urol Clin N Am (2004) 31:719

Basillote JB et al: J Urol (2004) 172:489

Taylor GD et al: J Urol (2004) 172:1291

Galich A et al: JSLS (2006) 10:145

Rhee JJ et al: BJU Int (2006) 98:1059

comparison of surgical techniques
Comparison of Surgical Techniques
  • Lymph node yield
  • Margin status
  • However, direct comparison between open and minimally invasive RC of early oncologic parameters is lacking.
study comparison
Study Comparison
  • Comparison of perioperative and early pathologic outcomes in a consecutive series of open and robotic RCs at our institution.
methods
Methods
  • From February to December 2006, 43 consecutive patients underwent RC by a single surgeon at our institution.
  • 22 open
  • 21 robotic
technique
Technique
  • Posterior dissection
  • Isolation of ureters
  • Lateral dissection
  • Control of bladder pedicles
  • Anterior dissection
  • Control of DVC and division of urethra
  • Control of prostate pedicles and nerve-sparing
  • Pelvic lymph node dissection
    • External iliac, hypogastric, and obturator lymphadenectomy up to the level of the mid-common iliac vessels
  • Extracorporeal urinary diversion through a 5-7cm midline incision
    • Orthotopic neobladder: robot re-docked for urethral neovesical anastomosis
data collection and analysis
Data Collection and Analysis
  • Data was collected prospectively
    • Patient characteristics
    • Perioperative outcomes
    • Early pathologic outcomes
  • Data analysis
    • Chi-square test
    • Fisher’s exact test
    • Student’s t-test
results patient characteristics
Results: Patient Characteristics
  • There was no difference in the following parameters among the 2 cohorts.
  • Age
  • BMI
  • ASA class
  • Prior abdominal surgery
  • Prior abdominal radiation
  • Neoadjuvant chemotherapy
operative time
Operative Time

* P < 0.05

conclusions robotic cystectomy
Conclusions:Robotic Cystectomy
  • Increased operative time
    • significantly longer operative time in the robotic neobladder cohort (p=0.01)
  • Decreased operative time with increased experience
    • 450 to 338 min (p=0.007)
conclusions robotic cystectomy1
Conclusions:Robotic Cystectomy
  • Decreased
    • Blood loss
    • Transfusion requirement
    • Time to regular diet
    • Length of hospital stay
conclusions robotic cystectomy2
Conclusions:Robotic Cystectomy
  • Equivalent lymph node yield
    • 17.4 (robotic) vs. 18.9 (open), p=0.6
  • Equivalent margin rate
    • 9% (robotic) vs. 19% (open), p=0.2
  • Long term oncologic and functional outcomes are required

Stein JP et al: J Urol (2003) 170: 35

Herr H et al: J Urol (2004) 171: 1823

minimally invasive cystectomy
Minimally Invasive Cystectomy
  • Minimally Invasive = Cancer Sparing
prostate sparing cystectomy
Prostate Sparing Cystectomy
  • Role for improved continence and potency
  • Need to rule out prostate cancer or TCC of prostatic urethra
  • Functional Results are good: a.) 97% complete continence b.) No episodes of retention c.) 82% maintained potency

Vallancien et al. J Urol, 168: 2413, 2002

prostate sparing cystectomy1
Prostate Sparing Cystectomy
  • Incidence of Pca is 30-50% with approx. 48% are clinically significant
  • 60% of CaP involve the apex (79% significant and 42% insignificant)
  • 48% of prostates had urothelial ca involvement of which 33% had apical involvement
  • 61% had no prostatic apical involvement of CaP or Urothelial ca.
ad